Voronoi, Inc.
310210.KQ - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.95T
Close$
$-681.54
100.7% downside
Current Fair Value
100.7% downsideOvervalued by 100.7% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $1.95 Trillion |
|---|---|
| Enterprise Value | $1.96 Trillion |
| Earnings per Share | $-2610.52 |
| Beta | 1.35 |
| Outstanding Shares | 18,349,248 |
Return
| Return on Equity | -107.61% |
|---|---|
| Return on Assets | -55.67% |
| Return on Invested Capital | -65.56% |
Valuation & Multiples
| P/E Ratio | -26.04 |
|---|---|
| PEG | -14.73 |
| Price to Sales | 447.79 |
| Price to Book Ratio | 26.84 |
| Enterprise Value to Revenue | 470.82 |
| Enterprise Value to EBIT | -24.42 |
| Enterprise Value to Net Income | -27 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.51 |
Revenue Sources
No data
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Voronoi, Inc.
149 employees
CEO: Daekwon Kim
Voronoi, Inc., founded in 2015 and based in Incheon, South Korea, is a biotechnology company dedicated to the research, development, and identification of small molecule kinase inhibitors. Its extensive product pipeline addresses various...